Skip to main content

CombiMatrix Q3 Revenues Decline 9 Percent as Firm Shifts Focus to Dx Market

NEW YORK (GenomeWeb News) – CombiMatrix yesterday reported a 9 percent dip in third-quarter revenues amid a double-digit decline in R&D spending and a smaller net loss.
For the quarter ended Sept. 30 -- its first as a standalone firm after splitting from Acacia Research in August -- revenue fell 9 percent to $1.7 million from $1.8 million in the comparable period of 2006.
“The decrease relative to 2006 was expected as we made a significant strategic shift in our commercial focus early in 2007 from selling R&D products to researchers to selling diagnostic products and services to physicians, patients and reference laboratories,” Amit Kumar, president and CEO of CombiMatrix, said in a statement.
Third-quarter revenues from government contracts fell to $627,000 from $725,000 in the prior-year period, while product sales dropped to $828,000 from $968,000 in the third quarter of 2006. Service contract revenue rose to $164,000 from $88,000 in the year-ago quarter.
R&D spending fell 32 percent to $1.9 million from $2.8 million in the comparable period of 2006.
CombiMatrix narrowed its net loss by 20 percent to $3.4 million from $4.3 million in the third quarter of 2006.
CombiMatrix had cash, cash equivalents, and short-term investments of $10.5 million as of Sept. 30.
The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.